CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells

被引：1

作者：

Wen, Yuanjia ^{[1
,2
]}

Xia, Yu ^{[1
,2
]}

Yang, Xiangping ^{[3
]}

Li, Huayi ^{[1
,2
]}

Gao, Qinglei ^{[1
,2
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Natl Clin Res Ctr Obstet & Gynecol,Dept Obstet & G, Wuhan, Peoples R China

[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll,Minist Educ, Key Lab Canc Invas & Metastasis,Hubei Key Lab Tumo, Wuhan, Peoples R China

[3] Guangzhou Med Univ, Affiliated Hosp 2, Guangdong Prov Key Lab Allergy & Clin Immunol, Guangzhou, Peoples R China

来源：

TRENDS IN IMMUNOLOGY | 2025年 / 46卷 / 02期

基金：

中国国家自然科学基金;

关键词：

CHEMOKINE RECEPTOR CCR8; ANTI-CCR8; ANTIBODY; CUTTING EDGE; NK CELLS; CANCER; ACTIVATION; POTENT; IDENTIFICATION; COMBINATION; CHEMOTAXIS;

D O I：

10.1016/j.it.2025.01.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tumor-infiltrating regulatory T (TI-Treg) cells constitute key components within the tumor microenvironment (TME) to suppress antitumor immunity and facilitate tumor progression. Although multiple therapies have been developed to eliminate TI-Treg cells, most of them exhibit only modest efficacy and harbor risks of inducing immune-related adverse events (irAEs). Recent studies demonstrate that CC chemokine receptor (CCR)8 is highly and specifically expressed on effector TI-Treg cells in mice and humans, highlighting CCR8 as a promising target for selective TI-Treg cell depletion in the treatment of various cancers. Here, we concentrate on the latest understanding of CCR8 regarding its expression, functions, and regulation, and summarize the current landscape of CCR8-targeted therapies. With favorable efficacy and safety, the latter represent an important class of next-generation putative cancer immunotherapies.

引用

页码：153 / 165

页数：13

共 89 条

[1] Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation [J].

Ali, Niwa ;

Zirak, Bahar ;

Rodriguez, Robert Sanchez ;

Pauli, Mariela L. ;

Hong-An Truong ;

Lai, Kevin ;

Ahn, Richard ;

Corbin, Kaitlin ;

Lowe, Margaret M. ;

Scharschmidt, Tiffany C. ;

Taravati, Keyon ;

Tan, Madeleine R. ;

Ricardo-Gonzalez, Roberto R. ;

Nosbaum, Audrey ;

Bertolini, Marta ;

Liao, Wilson ;

Nestle, Frank O. ;

Paus, Ralf ;

Cotsarelis, George ;

Abbas, Abul K. ;

Rosenblum, Michael D. .

CELL, 2017, 169 (06) :1119-+

[2] IRF4 instructs effector Treg differentiation and immune suppression in human cancer [J].

Alvisi, Giorgia ;

Brummelman, Jolanda ;

Puccio, Simone ;

Mazza, Emilia M. C. ;

Tomada, Elisa Paoluzzi ;

Losurdo, Agnese ;

Zanon, Veronica ;

Peano, Clelia ;

Colombo, Federico S. ;

Scarpa, Alice ;

Alloisio, Marco ;

Vasanthakumar, Ajithkumar ;

Roychoudhuri, Rahul ;

Kallikourdis, Marinos ;

Pagani, Massimiliano ;

Lopci, Egesta ;

Novellis, Pierluigi ;

Blume, Jonas ;

Kallies, Axel ;

Veronesi, Giulia ;

Lugli, Enrico .

JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (06) :3137-3150

[3] Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment [J].

Azizi, Elham ;

Carr, Ambrose J. ;

Plitas, George ;

Cornish, Andrew E. ;

Konopacki, Catherine ;

Prabhakaran, Sandhya ;

Nainys, Juozas ;

Wu, Kenmin ;

Kiseliovas, Vaidotas ;

Setty, Manu ;

Choi, Kristy ;

Fromme, Rachel M. ;

Phuong Dao ;

McKenney, Peter T. ;

Wasti, Ruby C. ;

Kadaveru, Krishna ;

Mazutis, Linas ;

Rudensky, Alexander Y. ;

Pe'er, Dana .

CELL, 2018, 174 (05) :1293-+

[4] First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors [J].

Babu, S. ;

Kondo, S. ;

Ammakkanavar, N. ;

Spira, A. I. ;

Perets, R. ;

Doi, T. ;

Bar, J. ;

Vandross, A. ;

Sommerhalder, D. ;

Nikolic, V. ;

Tribouley, C. ;

Atluri, H. ;

Hong, J. ;

Paustian, A. ;

Leibman, R. ;

Powderly, J. .

ANNALS OF ONCOLOGY, 2023, 34 :S647-S648

[5] CCR8+FOXp3+ Treg cells as master drivers of immune regulation [J].

Barsheshet, Yiftah ;

Wildbaum, Gizi ;

Levy, Eran ;

Vitenshtein, Alon ;

Akinseye, Chika ;

Griggs, Jeremy ;

Lira, Sergio A. ;

Karin, Nathan .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (23) :6086-6091

[6] I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo [J].

Bernardini, G ;

Spinetti, G ;

Ribatti, D ;

Camarda, G ;

Morbidelli, L ;

Ziche, M ;

Santoni, A ;

Capogrossi, MC ;

Napolitano, M .

BLOOD, 2000, 96 (13) :4039-4045

[7] Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models [J].

Campbell, Joseph R. ;

McDonald, Bryan R. ;

Mesko, Paul B. ;

Siemers, Nathan O. ;

Singh, Priti B. ;

Selby, Mark ;

Sproul, Tim W. ;

Korman, Alan J. ;

Vlach, Logan M. ;

Houser, Jeff ;

Sambanthamoorthy, Sharmila ;

Lu, Kai ;

Hatcher, Sandra, V ;

Lohre, Jack ;

Jain, Renu ;

Lan, Ruth Y. .

CANCER RESEARCH, 2021, 81 (11) :2983-2994

[8] CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease [J].

Coghill, James M. ;

Fowler, Kenneth A. ;

West, Michelle L. ;

Fulton, LeShara M. ;

van Deventer, Hendrik ;

McKinnon, Karen P. ;

Vincent, Benjamin G. ;

Lin, Kaifeng ;

Panoskaltsis-Mortari, Angela ;

Cook, Donald N. ;

Blazar, Bruce R. ;

Serody, Jonathan S. .

BLOOD, 2013, 122 (05) :825-836

[9] Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration [J].

Connolly, Stephen ;

Skrinjar, Marco ;

Rosendahl, Alexander .

BIOCHEMICAL PHARMACOLOGY, 2012, 83 (06) :778-787

[10]

D'Ambrosio D, 1998, J IMMUNOL, V161, P5111

← 1 2 3 4 5 6 7 8 9 →